Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Other Operating Expenses (2017 - 2025)

Ultragenyx Pharmaceutical has reported Other Operating Expenses over the past 9 years, most recently at $29.3 million for Q4 2025.

  • Quarterly Other Operating Expenses rose 70.95% to $29.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $109.0 million through Dec 2025, up 41.56% year-over-year, with the annual reading at $109.0 million for FY2025, 41.56% up from the prior year.
  • Other Operating Expenses was $29.3 million for Q4 2025 at Ultragenyx Pharmaceutical, up from $28.0 million in the prior quarter.
  • Over five years, Other Operating Expenses peaked at $29.3 million in Q4 2025 and troughed at $3.1 million in Q2 2021.
  • The 5-year median for Other Operating Expenses is $11.4 million (2023), against an average of $13.8 million.
  • Year-over-year, Other Operating Expenses crashed 93.86% in 2021 and then soared 163.71% in 2022.
  • A 5-year view of Other Operating Expenses shows it stood at $3.5 million in 2021, then soared by 51.58% to $5.3 million in 2022, then soared by 122.64% to $11.8 million in 2023, then surged by 44.96% to $17.2 million in 2024, then surged by 70.95% to $29.3 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Other Operating Expenses are $29.3 million (Q4 2025), $28.0 million (Q3 2025), and $23.0 million (Q2 2025).